Physician profile
John Howell
NPI 1871518225
$1,856.86
in general payments reported to CMS, 2019-2025
19 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $157 · 2021: $346 · 2022: $449 · 2023: $201 · 2024: $225 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.55 | 2020-2023 | |
| Novo Nordisk INC | $259.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Biotech, INC. | $211.51 | 2023-2024 | Tremfya |
| Genzyme Corporation | $115.49 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.42 | 2019 | |
| Pfizer INC. | $76.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.33 | 2019-2024 | Xifaxan, Trulance |
| Incyte Corporation | $60.00 | 2025 | Opzelura |
| Glaxosmithkline, LLC. | $37.49 | 2024-2025 | Arexvy, Shingrix, Bexsero |
| Axsome Therapeutics, INC. | $35.89 | 2025 | Symbravo, Auvelity |
| Astrazeneca Pharmaceuticals Lp | $30.82 | 2020-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $29.61 | 2020-2021 | |
| Esperion Therapeutics, INC. | $28.81 | 2021 | |
| Lilly USA, LLC | $28.09 | 2022 | |
| Daiichi Sankyo INC. | $21.08 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.18 | 2022 | |
| Amarin Pharma, INC. | $17.74 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.